The ACP1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from human Jurkat T lymphocytes, featuring targeted disruption of the ACP1 gene. This product delivers a heterogeneous pool of ACP1-deficient cells, avoiding clonal selection to maintain cellular diversity and reduce selection artifacts. The polyclonal format is particularly suited for reproducible functional assays, as it reflects a more physiologically relevant mixture of knockout phenotypes. The CRISPR/Cas9-mediated gene disruption ablates ACP1 protein expression, enabling comprehensive loss-of-function studies in immune signaling and leukemia research.
The parental Jurkat cell line originates from an acute T cell leukemia patient and serves as a classic model for T cell receptor (TCR) signaling, immune activation, and apoptosis. These suspension-adapted T lymphocytes retain functional expression of the TCR/CD3 complex and downstream effectors, recapitulating key aspects of primary T cell biology. Jurkat cells are widely used in immunology and oncology due to their ease of genetic manipulation and robust responses to TCR stimulation, making them an ideal host for investigating phosphatase-mediated regulation.
ACP1 encodes a low molecular weight phosphotyrosine phosphatase that functions as a critical negative regulator in multiple signaling networks. It dephosphorylates proteins such as Lck, ZAP70, EphA2, PDGF receptor, and insulin receptor, thereby controlling cell growth, differentiation, and immune responses. Within TCR signaling, ACP1 is activated by receptor stimulation and reactive oxygen species, and it interacts with Src family kinases and the adaptor Grb2 to terminate signaling. Knockout of ACP1 removes this inhibitory constraint, resulting in hyperphosphorylation of Lck and ZAP70, sustained activation of MAPK and NFAT pathways, and elevated IL-2 production, as described in mechanistic models.
In the Jurkat background, ACP1 disruption generates a hyper-responsive T cell phenotype mirroring pathological states observed in T cell acute lymphoblastic leukemia and autoimmune disorders. Unchecked phosphorylation events drive enhanced proliferation and cytokine secretion, providing a model to explore the role of phosphotyrosine phosphatases in disease. The polyclonal knock-out population ensures that functional observations are representative of diverse editing outcomes, reducing clonal bias and improving suitability for drug screening campaigns targeting immune modulators or phosphatase inhibitors.
Key applications include phospho-flow cytometry for phospho-Lck (Tyr394) and phospho-ZAP70 (Tyr319), western blotting of TCR signaling components, IL-2 ELISA, calcium flux assays, CD69 expression analysis by flow cytometry, and drug sensitivity testing. This tool supports research into T cell signaling dynamics, immune checkpoint mechanisms, and leukemia biology. For more details, validation data, and ordering, contact Ascent Research.
